Running title: Altering mammalian transcriptome with ADAADi ABSTRACT Transcriptional control has been earnestly pursued for the regulation of cellular proliferation associated with cancer progression. The foundational paradigm of targeting transcription factors has yielded exquisite specificity, but many factors cannot yet be targeted. In contrast, targeting epigenetic factors to control chromatin structure and consequential gene expression generally yields more global effects on transcription. Our working paradigm targets neither specific transcription factors nor global epigenetic factors but ATP-dependent chromatin remodeling factors that regulate expression of a limited set of genes. Active DNA-dependent ATPase A Domain inhibitor (ADAADi) synthesized by aminoglycoside phosphotransferases is the first-inclass inhibitor of ATP-dependent chromatin remodeling proteins that targets the ATPase domain of these proteins. Mammalian cells are sensitive to ADAADi but cell lines are variable in their individual responses to the inhibitor. The ADAADi product can be generated from a variety of aminoglycoside substrates with cells showing differential responses to ADAADi depending on the starting aminoglycoside. RNA seq analysis demonstrated that targeting the chromatin remodeling by treatment with a sub-lethal concentration of ADAADi yields alterations to the transcriptional network of the cell. Predominantly, the tumor-promoting genes were repressed while pro-apoptotic and tumor suppressors genes were upregulated on treatment with ADAADi, leading to apoptotic-type cell death. Treatment with ADAADi reversed the EMT process as well as inhibited migration of cells and their colony forming ability. In conjunction with the previous report that treatment with ADAADi regresses tumors in mouse model, this chromatin remodeling inhibitor shows promising anti-tumor properties by targeting the main hallmarks of cancer.
INTRODUCTION
Chromatin functions as both a structural and regulatory barrier for access to DNA by proteins and enzymes that effect metabolic processes including transcription, recombination, repair and replication, and thus also has an impact on cellular growth and differentiation.
Extensive knowledge of the nucleosomal structure of chromatin and the component histones and their post-translational modifiers has yielded a wealth of targets for low molecular weight inhibitors that target chromatin structure. Thus, deregulation of chromatin structure through epigenetic targeting of histone writers, histone erasers and histone readers is a burgeoning field of study with significant implications for the control of cancer cell growth 1,2 . Available evidence supports that cancer might be treated 2 or even prevented 3 by chemicals that affect epigenetic players and we have established that cancer progression can be limited through the use of ADAADi, an inhibitor of ATP-dependent chromatin remodeling 4 .
The body of knowledge regarding ADAADi spans its protein target, the regulation of transcription, the induction of apoptosis and even the clearance of solid tumors from an animal model 4-7 . Herein we add details regarding the impact of chromatin remodeling on cellular processes with particular interest in aspects of tumorigenesis and its progression.
The six hallmarks that dictate tumorigenesis and its progression are limitless replication, insensitivity to growth-inhibitory signals, self-sufficiency in growth signals, sustained angiogenesis, inhibition of apoptosis, and sustained tissue invasion and metastasis 8 . It has become increasingly evident that the genes regulating these pathways are regulated by chromatin remodeling, a mechanism involving histone modifications and nucleosome repositioning 9 .
The ATP-dependent chromatin remodeling proteins have been shown to participate in transcriptional regulation of gene expression by harnessing energy released by ATP hydrolysis to reposition nucleosomes 10 . These proteins have been classified into 24 sub-families based on phylogenetic analysis 11 .
Experimental evidence has shown that many of these proteins can function as tumor suppressor genes as well as drivers of cancer 12 . BRG1 and BRM, transcriptional regulators, have been shown to be mutated or mis-regulated in many cancers [13] [14] [15] . BRG1 has also been shown to cooperate with both BRCA1 and steroid receptors, thus, linking BRG1 to breast cancer 16, 17 . It is also a prognostic indicator for prostate cancer 4 . Loss of expression of BRG1/BRM has been correlated with poor prognosis in lung cancer 18 . The NuRD complex contains CHD/Mi-2 as the ATP-dependent chromatin remodeler and though, no mutations have been reported in this protein, yet it is known that the other components of the complex are altered in cancer tissues 19 . Of the other remodelers, though none of them have been studied for their direct role in tumorigenesis, it is known that many of them participate in DNA repair which is a mechanism intimately linked to cancer development and progression 20, 21 .
Therefore, these proteins have emerged as potential drug targets for cancer chemotherapy. While many inhibitors for the histone modifying enzymes are known, the inhibitors for the ATP-dependent chromatin remodeling proteins are limited in number and scope. Until now only PFI-3 targeting the bromodomain of BRG1 has been reported 22 . In addition to this inhibitor, we had earlier reported that the enzyme aminoglycoside (neomycin) phosphotransferase catalyzes the formation of a small molecule called Active DNA-dependent ATPase A domain inhibitor (ADAADi) that effectively inhibits the ATPase activity of the ATPdependent chromatin remodeling proteins 5 .
ADAADi is generated by the catalytic reaction mediated by aminoglycoside phosphotransferases using aminoglycosides as substrates 5,6 . Using fluorescence spectroscopy, Radhakrishnan, Rakesh/5
ADAADi was shown to bind to Active DNA-dependent ATPase A Domain (ADAAD) both in the absence as well as presence of ATP and DNA. This binding to ADAAD occurs via a specific conserved region previously identified as Motif Ia of the SWI2/SNF2 proteins leading to a conformational change in ADAAD that precludes ATP hydrolysis 6 . Thus, ADAADi has high specificity, targeting the DNA-driven conformational change that effects ATP hydrolysis which is essential for the chromatin remodeling.
The specificity with which ADAADi targets ATP-dependent chromatin remodeling proteins is remarkable since it neither inhibits other types of DNA-dependent ATPases nor DNA-independent ATPases 5 .
The cellular effects of ADAADi include reduction in the proliferation of mammalian cells lines like PC3, Neuro-2A and MCF-7 implicating a possible role of this molecule as a chemotherapeutic reagent 4,6,7 . Reinforcement of this concept of regulation of growth signal also emanates from the sensitivity of transcription to ADAADi in the breast cancer cell lines MDA-MB231, MDA-MB-468 and HDQ-P1 with recent studies showing that ADAADi targets BRG1 within the cell and therefore, functions as a potent BRG1 inhibitor 4,7 .
We have previously established efficacy in the pursuit of BRG1 as a chemotherapeutic target 4,7 and in this paper, we endeavor to delve into the complex matrix of effects that stem from the use of different ADAADi species in multiple mammalian cell lines. Each of the latter has its own distinct expression profile and epigenetic state which may account for their differential sensitivity to the ADAADi molecule and the induction of cell death through the apoptotic process. Finally, we also show that ADAADi disrupts the epithelial-to-mesenchymal transition, cell migration and colony formation indicating that the compound has the potential to inhibit some of the hallmark processes of cancer.
RESULTS

Cellular responsiveness to ADAADi is complex including time-dependent cellular
exposure: ADAADi was discovered as an inhibitor of ADAAD, which is the active ATPase protein domain from the bovine homolog of SMARCAL1 5 . Previous studies have shown that ADAADi can be used effectively to kill breast cancer cells 7 and prostate cancer cells 4 . We have expanded these observations to understand the effects of ADAADi on a wide range of cancer cell types and present the findings herein for eight cancer cell lines.
To quantitate the effect of ADAADi on mammalian cells, the time frame required for its action was first investigated. Mammalian cell lines were treated with neomycin-derived ADAADi (ADAADiN) for 24 hr and 48 hr and the viability of the cells was measured. The MTT assay showed that the treatment yielded greater alteration of cellular metabolism at 48 hr as compared to 24 hr ( Supplementary Fig. 1 ). Therefore, all subsequent experiments were done for 48 hr of ADAADi treatment unless otherwise stated. The IC 50, in each case, at 48 hr was found to be greater than at 24 hr (Table 1 ; Supplementary Fig. 1 ). It should be noted that in case of mechanism-based inhibition, the IC 50 values depend on the time and therefore, the values are different at 24 and 48 hr 23 .
Responsiveness to ADAADi is a function of both the ADAADi derivative and the mammalian cell line:
ADAADi can be generated from many different aminoglycosides 6 . We hypothesized that the ADAADi derived from structurally different starting substrates could have differential effects on mammalian cell lines. To address this postulate, mammalian cancer cell lines were treated with ADAADi generated from neomycin (ADAADiN) or kanamycin (ADAADiK), with the former having four glycosidic rings and the latter having only three glycosidic rings. After 48 hr of treatment, cell lines displayed differential sensitivity to the inhibitors ( Supplementary Fig. 1B ; Table 1) . As an example, the L132 cell line is derived from HeLa cells but this former cell line is extremely resistant to ADAADiK as compared to HeLa even though the cell lines show comparable sensitivity to ADAADiN. Two cell lines (DU145 and PC3) derived from prostate tissue demonstrated comparable sensitivity to ADAADiN but also responded roughly equally to ADAADiK. Unlike the prostate cells, MDA-MB-231 breast cancer cells were most sensitive to ADAADiK while the MCF-7 breast cancer cell line was dramatically more sensitive to ADAADiN. Overall, 7 of the 9 cell lines yielded sensitivity to ADAADiN that was equal to or greater than that of ADAADiK with the exceptions being cell lines HEK293 and MDA-MB-231 which were demonstrably more sensitive to the ADAADiK.
However, we were unable to establish any simple rules for the potency of the ADAADi inhibitors either with respect to the origin of the cell line or with respect to type of cell line (Table 1) .
The responsiveness of cells is not dependent on the status of SMARCAL1 or BRG1
alone: To understand the effect of ADAADi at the molecular level, we turned our attention to the expression of SMARCAL1 and BRG1 as we have previously established the sensitivity of SMARCAL1 and BRG1 proteins to ADAADi 5,6 .
We hypothesized that the responsiveness of the cell to ADAADi would be dependent on the presence or absence of SMARCAL1 and/or BRG1. Thus, a cell line that expresses both SMARCAL1 and BRG1 would be more sensitive as compared to a cell line that expresses either SMARCAL1 or BRG1 while a cell line that expresses neither SMARCAL1 nor BRG1 would be least responsive to ADAADi. To test the hypothesis, the expression of the two proteins in the cancer cell lines was analyzed using western blot (Fig. 1A) . The expression of these proteins when compared to responsiveness of cells to ADAADi demonstrated no correlation between the expression of SMARCAL1 or BRG1 and the responsiveness of the cells to ADAADi (Compare Fig. 1A and Table 1 ). For example, BRG1 is absent in A549 and DU145 cells ( In all the subsequent experiments we used HeLa cells as they expressed both BRG1 and SMARCAL1. We have treated Hela cells with 5 μM ADAADiN for 48 hr in all the experiments described henceforth.
The transcriptomic profile of HeLa cells is altered on treatment with ADAADiN:
ADAADiN treatment leads to an increase in the transcript levels of SMARCAL1 and BRG1 ( Fig. 1F ). However, the protein produced is inactive as observed by reduced ATPase activity in the cases of both SMARCAL1 (retains only 46% activity) and BRG1 (retains only 26% activity) in HeLa cells after 48 of treatment ( Fig. 1G ). The ATPase activity of these proteins is needed for co-regulating transcription [24] [25] [26] [27] . Also, we had previously shown that cell line resistant to ADAADiN showed decreased ATPase activity of SMARCAL1 and BRG1 that manifested in alterations in the transcriptomic profile of the cells 6 . Therefore, we hypothesized that the inactivation of the ATP-dependent chromatin remodeling proteins by ADAADiN would alter the transcriptome of cells. To this end, we treated HeLa cells with ADAADiN for 48 hr and RNAseq was performed on the isolated transcripts. The RNA-seq data was analyzed using Salmon, DESeq2 taking UCSC known gene file as reference transcriptome to identify the differentially expressed genes. The data was analyzed using two biological replicates, normalized (Supplementary Fig. 2A ) and analysis showed good correlation as well as mean-variance relationship between the replicates ( Supplementary Fig. 2B and C).
About 800 genes that were involved in protein targeting, metabolic processes and protein translation were found to be differentially regulated (p< 0.05) (Supplementary Excel File 1). The heat map of the top 100 (p<0.05) differentially expressed genes between the untreated and treated samples showed that there was consistency between the replicates and that there are more downregulated genes as compared to upregulated genes on ADAADiN treatment ( Fig. 1H) . A volcano plot too was generated to observe the overall differences between the untreated and ADAADiN treated samples (Fig. 1I ). The plot showed that the expression of 537 genes was altered (p<0.05) by 1.5 fold ( Fig. 1I ). Gene ontology showed that the differentially expressed genes included regulated protein targeting to ER, ATP metabolic processes, ribosome assembly, and ribosome biogenesis pathways ( Fig. 1J ). Pathway analysis using KEGG also showed that 49 genes involved in apoptosis and 75 genes involved in cell cycle are differentially expressed on ADAADiN treatment ( Fig. 1K ). SMARCAL1 and BRG1 were upregulated, as we had found by qPCR (see Fig. 1F ), but the change in their expression as well in the expression of other ATPdependent chromatin remodeling proteins was not statistically significant (Supplementary Excel File 1). Further, the transcripts encoding for ABCG1, ABCB1, and ABCG2 proteins (multi-drug resistance pumps) were found to be unaltered in the case of HeLa cells. This is consistent with the lack of change in basal transcription previously reported for MDA-MB-231 cells but which is unlike the effect of ADAADiN upon transcription of these genes when induced by a variety of chemotherapeutic reagents wherein ADAADiN treatment prevents the upregulation of these pumps 7 . Thus, we infer that basal regulation of ABC cassette genes by ATP-dependent chromatin remodelers may employ different mechanisms than the upregulation of the same genes.
As RNA-seq data showed some of the splicing factors are altered on ADAADiN treatment, we inquired whether ADAADiN treatment is causing the change in transcript usage after the treatment. For this purpose, the data was also analyzed using the GENCODE reference transcriptome and nearly 60 percent correlation of differentially expressed genes (log2foldchange>1.3) was observed between the two analyses. The differential transcript usage on RNA-seq data obtained when GENECODE reference transcriptome was used was analyzed by DTUrnaseq-DRIMSeq package. We used GENECODE data for the splice variant usage analysis because it contains considerably more annotated and predicted transcripts annotation than the known gene reference transcriptome. Our analysis showed that about 900 genes were switching to alternate transcripts after ADAADiN treatment (Supplementary Excel File 2).
To identify the genome wide occupancy of SMARCAL1 and BRG1 with the implication of a better understanding of the transcriptome regulation by these ATP-dependent chromatin remodeling proteins, ChIP-seq was performed using antibodies against SMARCAL1 and BRG1.
We employed, untreated HeLa cells. Unsupervised k-mean clustering (k=5) of ChIP-seq peaks showed that the two proteins are present on the transcription start sites (TSS) ( Fig. 2A ) and their peak overlap showed that these proteins co-occupy 8755 sites on the genome ( Fig. 2B ; Supplementary Excel File 3 and 4). Previously, we had shown that SMARCAL1 was present on BRG1 promoter and BRG1 was present on SMARCAL1 promoter 24 . The ChIP-seq data validated our experimental results ( Fig. 2C ; Supplementary Excel File 3 and 4) as SMARCAL1 and BRG1 were found to be present on SMARCAL1 and BRG1 genes. SMARCAL1 and BRG1
were also found on the promoter of ATM gene (Fig. 2C ), once again validating the experimental results obtained in previous studies 26 . Finally, we analyzed the presence of these two proteins on ABC transporters as previously BRG1 has been shown to regulate the expression of these genes in breast cancer cells 7 . The ChIP seq data showed that both BRG1 and SMARCAL1 are also present on ABCG1, ABCB1, and ABCG2 genes ( Supplementary Fig. 2D ), even though their expression does not alter on ADAADiN treatment (Supplementary Excel File 1). Interestingly, peak analysis on the genome browser showed that SMARCAL1 and BRG1 were also found to occupy intronic regions specially the first intron of several genes.
Using a less stringent condition p<0.1 led us to identify 1710 differentially regulated genes of which 484 genes (28.3% genes) were found to be regulated by SMARCAL1 and BRG1 either alone or by a combination of the two proteins ( Fig. 2D ). The genes co-regulated by SMARCAL1 and BRG1 include ROCK2 and EGF ( Fig. 3A ; Supplementary Excel File 3 and 4).
ROCK2 is a Rho-associate protein kinase 2 involved in many cellular pathways including apoptosis 28 , while EGF is a growth factor.
To validate the ChIP seq data obtained in our experiments, we compared it with the dataset for BRG1 available in public domain and confirmed that BRG1 in both experiments was indeed present on SMARCAL1, BRG1, ATM, ROCK2, and EGF ( Supplementary Fig. 3 ) Finally, we sought to experimentally validate the RNA-seq data using qPCR. We picked genes where the occupancy of SMARCAL1 and BRG1 was predicted by ChIP-seq data (ROCK2, EGF, CENPE, and KMT2A) as well as those genes where the occupancy of these two proteins was not shown by ChIP-seq data (DCTN3, SNAPC2, MALAT1, CEP135 and EMP3).
Experimental results showed that the expression of ROCK2, CENPE, CEP135, MALAT1, EGF was downregulated while the expression of DCTN3, SNAPC2, and EMP3, was upregulated correlating with the RNA-seq data (Fig. 3B ). The expression of KMT2A was unaltered though the RNA-seq data indicated that the expression of this gene was significantly upregulated ( Fig.   3B ). Thus, of the 9 genes, we were able to validate the RNA-seq data for 8 genes by experimentation.
ADAADiN treatment induces DNA damage in a cell type specific manner: RNA-seq
data as well as qPCR confirmed that the expression of ATM, the transducer of DNA damage signal, was downregulated (p<0.05) ( Fig. 4A ) in HeLa cells. Since ATM as well as many ATPdependent chromatin remodeling proteins directly mediate DNA damage response/repair 29 , we hypothesized that downregulation of ATM expression coupled with inactivation of ATPdependent chromatin remodeling proteins should result increased DNA damage. To test the hypothesis, we investigated the formation of γH2AX 30, 31 and 53BP1 foci 32 and found to our surprise, that in HeLa cells, neither γH2AX nor 53BP1 foci were observed indicating that DNA damage is not induced in these cells (Fig. 4B ). This was further confirmed by comet assay (Fig.   4C and D). To confirm that DNA damage is indeed not induced, we studied the effect of ADAADiN in DU145 cells that do not express SMARCAL1 and BRG1. In these cells, ATM, was found to be upregulated on ADAADiN treatment ( Fig. 4A ). Further in these cells, γH2AX The process of epithelial-to-mesenchymal transition (EMT) is known to make the cells shed their epithelial characteristics to acquire more mesenchymal phenotype which is metastatic and renders resistance to chemotherapeutic drugs. Upon examining the RNA-seq data it was found that the genes (VIM, FN1, CDH1, and CDH2) associated with EMT were not significantly differentially expressed on ADAADiN treatment. However, ChIP-seq data showed that SMARCAL1 and BRG1 are present on VIM, CDH1, and CDH2 (Supplementary Excel File 3-5).
It has also been shown previously that ADAADiN treatment makes the metastatic cells, MDA-MB-231 more sensitive to chemotherapy 7 . One plausible explanation for this could be that SMARCAL1 and BRG1 do not regulate the basal transcription of EMT genes and act only upon EMT inducing signal. Therefore, to investigate the role of ADAADiN in the process of EMT, HeLa and DU145 cells were treated with EMT inducing agent TGF-β1 alone or with ADAADiN for 48 hr. Treatment with TGF-β1 alone decreased the transcript levels of the pro-epithelial marker, E-cadherin (CDH1), in both HeLa and DU145 cells ( Fig. 6A and B) ; however, the addition of ADAADiN along with TGF-β1 resulted in the increased expression of CDH1 ( Fig.  6A and B). Fibronectin (FN1), N-cadherin (CDH2), Vimentin (Vim) are pro-mesenchymal whose increased expression has been correlated with EMT 40 . In DU145 cells, the expression of FN1 and CDH2 decreased while in HeLa the expression of VIM decreased when these cell lines were treated with ADAADiN along with TGF-β1 as compared to TGF-β1 alone ( Fig. 6A and B ).
EMT is also characterized with decreased expression of Claudin-1 40 ; western blots confirmed that the expression of Claudin-1 as well N-cadherin returned back to normal levels when the cells were treated with ADAADi and TGF-β1 ( Fig. 6C and D ), suggesting that ADAADiN treatment does alter the expression of proteins when EMT is induced with TGF-β1; however, the inhibitor has no effect on the basal levels expression of the genes associated with the process.
The morphology of the cells was also studied under microscope and the epithelial phenotype of the cells in the presence of ADAADiN and TGF-β1 as was compared to TGF-β alone was evident when analyzed using microscope ( Fig. 6E ).
Taken together, these results led us to conclude that ADAADiN treatment of cancer cells pushes them towards epithelial phenotype, thus, preventing or delaying TGF-β1-induced transition into mesenchymal phenotype.
ADAADiN treatment inhibits migration and invasion of cancer cells: Since
ADAADiN was found to inhibit the process of EMT which makes the cells more invasive and migratory, we next investigated the levels of matrix metalloproteinases as their role in cancer metastasis has been well-established 41 . These proteins are secreted into the extracellular milieu where they promote cancer cell migration by degrading the physical barriers. Both MMP-2 and MMP-9 expression has been shown to be associated with tumor aggressiveness and poor prognosis 41, 42 . ChIP-seq data showed that BRG1 and SMARCAL1 are present on MMP-2 and MMP-9 promoter (Supplementary Excel File 3-4). ADAADiN treatment resulted in decreased expression of MMP-2 and MMP-9 transcripts in both HeLa and DU145 cells (Fig. 7A ). RNAseq data too confirmed that these transcripts are downregulated but not in a statistically significant manner (Supplementary Excel File 1). Further, pro-MMP-2 secretion in HeLa cells and pro-MMP-9 secretion in DU145 cells decreased on ADAADi treatment as observed by zymography assay (Fig. 7B-E) . Concomitantly, wound healing assay in both HeLa and DU145 cells showed that the ability to heal the wound was considerably retarded on ADAADiN treatment ( Fig. 7F-I) .
Taken together, it leads us to conclude that ADAADiN treatment has the potential to retard the invasiveness of cancer cells by altering the expression of metalloproteases and EMT genes.
ADAADiN inhibits the clonogenicity of the cancer cells: Limitless replication is yet
another hallmark of cancer cells. We hypothesized that ADAADiN should be able to inhibit the ability of cancer cells to replicate indefinitely. To test this hypothesis, colony forming assay was performed as explained in the Methods section. Two conditions were used to analyze whether ADAADiN can inhibit colony formation. In the first condition, ADAADiN was added after seeding the cells in the agar containing media. The colony formation ability was determined in the presence of ADAADiN for 12 days. In the second condition, cells were pre-treated with ADAADiN for 24 hr. These cells were seeded in the agar containing media and were allowed to grow in DMEM media that lacked the inhibitor (termed as "pre-treated and discontinued").
ADAADiN treatment reduced the colony forming ability of both HeLa and DU145 cells as compared to the untreated control as measured by relative area of the colony and Hoechst staining ( Fig. 8A-D) . Interestingly, pre-treated and discontinued condition also resulted in decreased colony forming ability, suggesting that pre-treatment of cells with ADAADiN is sufficient to block the ability of the cancer cells to replicate indefinitely ( Fig. 8A-D) .
DISCUSSION
The ATP-dependent chromatin remodeling proteins function as co-regulators of transcription in eukaryotic cells. By coupling ATP hydrolysis to nucleosome repositioning, eviction or histone variant exchange, these proteins are able to regulate the expression of a subset of genes, and therefore, the cellular function 10 multiple examples of genes for which ADAADi has no effect on the basal transcription but whose regulation by various secondary methods are mitigated by the presence of the ADAADi.
Thus, the control of ATP-dependent remodeling provides a plausible avenue for control of processes such as cell migration and EMT, as well as transcriptome alterations impacting a wide range of properties of cancer cells. The alteration in transcriptome on ADAADi treatment induces apoptosis, inhibits metastasis, and inhibits replication ability of cancer cells. Our work lays the preliminary foundation demonstrating that ADAADi treatment of cells provides a mechanism for regulation of a discrete subset of all genes, as well as regulation of induced alterations in the transcriptional network of mammalian cells.
The RNA-seq data also revealed that the subset of ADAADi-impacted genes included both protein-coding as well as non-coding transcripts. Moreover, within the subset of proteincoding genes there are a few genes that are associated with cancer progression that show distinctive downregulation by ADAADi treatment, including EGF, CENPE 46 Thus, through its targeting of ATP-dependent remodeling, ADAADi is unlike any other known epigenetic inhibitor. While less specific than targeting a specific transcription factor such as a steroid receptor, ADAADi nevertheless demonstrates sufficient specificity to avoid broad global effects that would lead to general cell death. The demonstrable effects that we document herein illustrate a great chemotherapeutic potential of this novel class of drugs that warrants additional development and prompt evaluation both as an individual and a combinatorial chemotherapeutic approach to cancer treatment.
METHODS
Chemicals:
All chemicals were of analytical grade and were purchased from Sigma-Aldrich (USA), Qualigens (India), Merck (India), Himedia (India) and SRL (India). LB media was purchased from Himedia (India). Ni +2 -NTA resin, Protein G beads and Taq polymerase were purchased from Merck-Millipore (USA). cDNA synthesis kit was purchased from Thermo-Fisher (USA). Biorex-70 resin was purchased from Bio-Rad (USA). Cell culture chemicals were purchased from Sigma-Aldrich (USA) while cell culture plasticware was from Corning (USA). SYBR Green mix was purchased from Kapa Biosystems (USA).
Antibodies: SMARCAL1 antibody was raised against N-terminus HARP domain by
Merck (India) (Catalog # 106014). BRG1 (Catalog# B8184) and β-actin (Catalog# A1978) antibodies were purchased from Sigma-Aldrich (USA). Radhakrishnan, Rakesh/26
Comet assay: Single cell gel electrophoresis was performed as described by Nandhakumar et al. 49 . Briefly, HeLa cells were grown till they were 60-70% confluent and then given treatment with 5 µM ADAADiN for the desired time period. After appropriate treatment, the cells were washed in cold 1X PBS, trypsinized and resuspended in ice-cold PBS. The cell suspension containing 10 4 cells/slide was embedded in 100 µl of 1% low-melting agarose Orange/Ethidium bromide staining as per the protocol described by Ribble et al. 51 . Quantitation and analysis was done as described by Anasamy et al. 37 . Colony formation monitored in untreated, ADAADiN treated, and ADAADiN pre-treated followed by discontinuation of the inhibitor in DU145 cells. On the 16 th day, the colonies were stained with Hoechst. Images were taken using Nikon TiS microscope.
Colony formation assay
